Editas Medicine, Inc. 10-Q

Item 1. Financial Statements. Editas Medicine, Inc. Condensed Consolidated Balance Sheets (unaudited) (amounts in thousands, except share and per share data) ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ ​ 2021 ​ 2020 ASSETS ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 259,884 ​ $ 139,682 Marketable securities ​ ​ 297,957 ​ ​ 262,428 Accounts receivable ​ 251 ​ 6,048 Prepaid expenses and other current assets ​ 9,516 ​ 10,929 Total current assets ​ 567,608 ​ 419,087 Marketable securities ​ ​ 99,198 ​ ​ 109,664 Property and equipment, net ​ 15,631 ​ 14,020 Right-of-use assets ​ ​ 27,801 ​ ​ 25,128 Restricted cash and other non-current assets ​ 6,781 ​ 4,703 Total assets ​ $ 717,019 ​ $ 572,602 LIABILITIES AND STOCKHOLDERS’ EQUITY ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ Accounts payable ​ $ 3,402 ​ $ 6,408 Accrued expenses ​ 14,575 ​ 24,046 Deferred revenue, current ​ ​ 22,667 ​ ​ 20,943 Operating lease liabilities ​ ​ 10,263 ​ ​ 6,811 Total current liabilities ​ 50,907 ​ 58,208 Operating lease liabilities, net of current portion ​ ​ 18,430 ​ ​ 19,324 Deferred revenue, net of current portion ​ ​ 60,888 ​ ​ 73,984 Other non-current liabilities ​ — ​ 27,500 Total liabilities ​ ​ 130,225 ​ ​ 179,016 Stockholders’ equity ​ ​ ​ ​ ​ ​ Preferred stock, $ 0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding ​ — ​ — Common stock, $ 0.0001 par value per share: 195,000,000 shares authorized; 68,392,659 and 62,689,457 shares issued, and 68,320,659 and 62,563,457 shares outstanding at September 30, 2021 and December 31, 2020, respectively ​ 7 ​ 6 Additional paid-in capital ​ 1,403,114 ​ 1,058,823 Accumulated other comprehensive loss ​ ​ ( 64 ) ​ ​ ( 46 ) Accumulated deficit ​ ( 816,263 ) ​ ( 665,197 ) Total stockholders’ equity ​ ​ 586,794 ​ ​ 393,586 Total liabilities and stockholders’ equity ​ $ 717,019 ​ $ 572,602 ​ The accompanying notes are an integral part of the condensed consolidated financial statements. ​ 3 Table of Contents Editas Medicine, Inc. Condensed Consolidated Statement of Operations (unaudited) (amounts in thousands, except share and per share data) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Collaboration and other research and development revenues ​ $ 6,197 ​ $ 62,841 ​ $ 13,075 ​ $ 79,313 Operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ 29,265 ​ 33,916 ​ 104,954 ​ 96,492 General and administrative ​ 16,185 ​ 19,936 ​ 59,657 ​ 51,789 Total operating expenses ​ 45,450 ​ 53,852 ​ 164,611 ​ ​ 148,281 Operating (loss) income ​ ( 39,253 ) ​ 8,989 ​ ( 151,536 ) ​ ( 68,968 ) Other income (expense), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense), net ​ 19 ​ ( 1,396 ) ​ 38 ​ 13,114 Interest income, net ​ ​ 152 ​ ​ 226 ​ ​ 432 ​ ​ 2,377 Total other income (expense), net ​ 171 ​ ( 1,170 ) ​ 470 ​ 15,491 Net (loss) income ​ $ ( 39,082 ) ​ $ 7,819 ​ $ ( 151,066 ) ​ $ ( 53,477 ) Net (loss) income per share, basic ​ $ ( 0.57 ) ​ $ 0.13 ​ $ ( 2.24 ) ​ $ ( 0.93 ) Net (loss) income per share, diluted ​ $ ( 0.57 ) ​ $ 0.12 ​ $ ( 2.24 ) ​ $ ( 0.93 ) Weighted-average common shares outstanding, basic ​ ​ 68,219,742 ​ ​ 62,144,118 ​ 67,371,246 ​ 57,377,581 Weighted-average common shares outstanding, diluted ​ ​ 68,219,742 ​ ​ 62,697,173 ​ ​ 67,371,246 ​ ​ 57,377,581 ​ ​ The accompanying notes are an integral part of the condensed consolidated financial statements. ​ 4 Table of Contents Editas Medicine, Inc. Condensed Consolidated Statements of Comprehensive (Loss) Income (unaudited) (amounts in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ ​ 2021 ​ 2020 ​ 2021 ​ 2020 Net (loss) income ​ $ ( 39,082 ) ​ $ 7,819 ​ $ ( 151,066 ) ​ $ ( 53,477 ) Other comprehensive (loss) income: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized gain (loss) on marketable debt securities ​ 7 ​ ( 231 ) ​ ( 18 ) ​ ( 155 ) Comprehensive (loss) income ​ $ ( 39,075 ) ​ $ 7,588 ​ $ ( 151,084 ) ​ $ ( 53,632 ) ​ The accompanying notes are an integral part of the condensed consolidated financial statements. ​ ​ ​ ​ ​ 5 Table of Contents Editas Medicine, Inc. Condensed Consolidated Statements of Stockholders’ Equity (unaudited) (amounts in thousands, except share data) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ Other ​ Other ​ Total ​ ​ Common Stock ​ Paid-In ​ Comprehensive ​ Accumulated ​ Stockholders’ ​ ​ Shares Amount ​ Capital ​ Loss ​ Deficit ​ Equity Balance at December 31, 2020 ​ 62,563,457 ​ $ 6 ​ $ 1,058,823 ​ $ ( 46 ) ​ $ ( 665,197 ) ​ $ 393,586 Issuance of common stock for public offering ​ 4,025,000 ​ ​ 1 ​ ​ 249,458 ​ ​ — ​ ​ — ​ ​ 249,459 Issuance of common stock for success payment ​ 303,599 ​ ​ — ​ ​ 27,500 ​ ​ — ​ ​ — ​ ​ 27,500 Exercise of stock options ​ 501,162 ​ ​ — ​ ​ 12,002 ​ ​ — ​ ​ — ​ ​ 12,002 Vesting of restricted common stock awards ​ 79,397 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Stock-based compensation expense ​ — ​ ​ — ​ ​ 12,204 ​ ​ — ​ ​ — ​ ​ 12,204 Unrealized loss on marketable debt securities ​ — ​ ​ — ​ ​ — ​ ​ ( 27 ) ​ ​ — ​ ​ ( 27 ) Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 56,728 ) ​ ​ ( 56,728 ) Balance at March 31, 2021 ​ 67,472,615 ​ $ 7 ​ $ 1,359,987 ​ $ ( 73 ) ​ $ ( 721,925 ) ​ $ 637,996 Exercise of stock options ​ 629,973 ​ ​ — ​ ​ 16,567 ​ ​ — ​ ​ — ​ ​ 16,567 Stock-based compensation expense ​ — ​ ​ — ​ ​ 13,526 ​ ​ — ​ ​ — ​ ​ 13,526 Vesting of restricted common stock awards ​ 37,790 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Purchase of common stock under benefit plans ​ 19,408 ​ ​ — ​ ​ 526 ​ ​ — ​ ​ — ​ ​ 526 Unrealized gain on marketable debt securities ​ — ​ ​ — ​ ​ — ​ ​ 2 ​ ​ — ​ ​ 2 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 55,256 ) ​ ​ ( 55,256 ) Balance at June 30, 2021 ​ 68,159,786 ​ $ 7 ​ $ 1,390,606 ​ $ ( 71 ) ​ $ ( 777,181 ) ​ $ 613,361 Exercise of stock options ​ 86,985 ​ ​ — ​ ​ 2,496 ​ ​ — ​ ​ — ​ ​ 2,496 Stock-based compensation expense ​ — ​ ​ — ​ ​ 10,012 ​ ​ — ​ ​ — ​ ​ 10,012 Vesting of restricted common stock awards ​ 73,888 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Unrealized gain on marketable debt securities ​ — ​ ​ — ​ ​ — ​ ​ 7 ​ ​ — ​ ​ 7 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 39,082 ) ​ ​ ( 39,082 ) Balance at September 30, 2021 ​ 68,320,659 ​ $ 7 ​ $ 1,403,114 ​ $ ( 64 ) ​ $ ( 816,263 ) ​ $ 586,794 ​ ​ 6 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ Other ​ Other ​ Total ​ ​ Common Stock ​ Paid-In ​ Comprehensive ​ Accumulated ​ Stockholders’ ​ ​ Shares Amount ​ Capital ​ Income (Loss) ​ Deficit ​ Equity Balance at December 31, 2019 ​ 54,355,798 ​ $​ 5 ​ $​ 811,546 ​ $​ 107 ​ $​ ( 549,221 ) ​ $ 262,437 Exercise of stock options ​ 233,208 ​ ​ — ​ ​ 3,047 ​ ​ — ​ ​ — ​ ​ 3,047 Vesting of restricted common stock awards ​ 213,393 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Stock-based compensation expense ​ — ​ ​ — ​ ​ 6,220 ​ ​ — ​ ​ — ​ ​ 6,220 Unrealized gain on marketable debt securities ​ — ​ ​ — ​ ​ — ​ ​ 587 ​ ​ — ​ ​ 587 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 37,724 ) ​ ​ ( 37,724 ) Balance at March 31, 2020 ​ 54,802,399 ​ $ 5 ​ $ 820,813 ​ $ 694 ​ $ ( 586,945 ) ​ $ 234,567 Exercise of stock options ​ 355,812 ​ ​ — ​ ​ 6,839 ​ ​ — ​ ​ — ​ ​ 6,839 Issuance of common stock for public offering ​ 6,900,000 ​ ​ 1 ​ ​ 203,681 ​ ​ — ​ ​ — ​ ​ 203,682 Stock-based compensation expense ​ — ​ ​ — ​ ​ 5,417 ​ ​ — ​ ​ — ​ ​ 5,417 Vesting of restricted common stock awards ​ 30,194 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Purchase of common stock under benefit plans ​ 15,244 ​ ​ — ​ ​ 350 ​ ​ — ​ ​ — ​ ​ 350 Unrealized loss on marketable debt securities ​ — ​ ​ — ​ ​ — ​ ​ ( 511 ) ​ ​ — ​ ​ ( 511 ) Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 23,572 ) ​ ​ ( 23,572 ) Balance at June 30, 2020 ​ 62,103,649 ​ $ 6 ​ $ 1,037,100 ​ $ 183 ​ $ ( 610,517 ) ​ $ 426,772 Exercise of stock options ​ 48,312 ​ ​ — ​ ​ 947 ​ ​ — ​ ​ — ​ ​ 947 Stock-based compensation expense ​ — ​ ​ — ​ ​ 5,845 ​ ​ — ​ ​ — ​ ​ 5,845 Vesting of restricted common stock awards ​ 35,739 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Unrealized loss on marketable debt securities ​ — ​ ​ — ​ ​ — ​ ​ ( 231 ) ​ ​ — ​ ​ ( 231 ) Net income ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 7,819 ​ ​ 7,819 Balance at September 30, 2020 ​ 62,187,700 ​ $ 6 ​ $ 1,043,892 ​ $ ( 48 ) ​ $ ( 602,698 ) ​ $ 441,152 ​ ​ ​ ​ ​ ​ The accompanying notes are an integral part of the condensed consolidated financial statements. 7 Table of Contents Editas Medicine, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) (amounts in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ September 30, ​ 2021 2020 Cash flow from operating activities ​ ​ ​ ​ ​ ​ Net loss ​ $ ( 151,066 ) ​ $ ( 53,477 ) Adjustments to reconcile net loss to net cash used in operating activities: ​ ​ ​ ​ ​ ​ Stock-based compensation expense ​ 35,742 ​ 17,483 Depreciation ​ 3,542 ​ 2,776 Unrealized gain on corporate equity securities ​ ​ — ​ ​ ( 13,109 ) Other non-cash items, net ​ 1,332 ​ ( 285 ) Changes in operating assets and liabilities: ​ ​ ​ ​ Accounts receivable ​ ​ 5,797 ​ ​ ( 637 ) Prepaid expenses and other current assets ​ ​ 1,414 ​ ​ ( 4,181 ) Right-of-use assets ​ ​ 7,080 ​ ​ 2,363 Other non-current assets ​ ​ ( 2,077 ) ​ ​ 106 Accounts payable ​ ​ ( 2,978 ) ​ ​ ( 447 ) Accrued expenses ​ ​ ( 9,439 ) ​ ​ ( 2,391 ) Deferred revenue ​ ( 11,372 ) ​ ( 86,026 ) Operating lease liabilities ​ ( 7,196 ) ​ ( 2,371 ) Other current and non-current liabilities ​ ​ — ​ ​ 453 Net cash used in operating activities ​ ( 129,221 ) ​ ( 139,743 ) Cash flow from investing activities ​ ​ ​ ​ ​ ​ Purchases of property and equipment ​ ( 5,132 ) ​ ​ ( 5,786 ) Proceeds from the sale of equipment ​ ​ — ​ ​ 21 Purchases of marketable securities ​ ​ ( 304,570 ) ​ ​ ( 300,363 ) Proceeds from maturities of marketable securities ​ ​ 278,076 ​ ​ 274,500 Net cash used in investing activities ​ ( 31,626 ) ​ ( 31,628 ) Cash flow from financing activities ​ ​ ​ ​ ​ ​ Proceeds from offering of common stock, net of issuance costs ​ ​ 249,458 ​ ​ 203,839 Proceeds from exercise of stock options ​ ​ 31,065 ​ ​ 10,833 Issuance of common stock under benefit plans ​ ​ 526 ​ ​ 350 Net cash provided by financing activities ​ 281,049 ​ 215,022 Net increase in cash, cash equivalents, and restricted cash ​ 120,202 ​ ​ 43,651 Cash, cash equivalents, and restricted cash, beginning of period ​ 143,559 ​ ​ 239,802 Cash, cash equivalents, and restricted cash, end of period ​ $ 263,761 ​ $ 283,453 Supplemental disclosure of cash and non-cash activities: ​ ​ ​ ​ ​ ​ Fixed asset additions included in accounts payable and accrued expenses ​ $ 597 ​ $ 910 Cash paid in connection with operating lease liabilities ​ ​ 8,918 ​ ​ 7,757 Offering costs included in accounts payable and accrued expenses ​ ​ — ​ ​ 158 Right-of-use assets obtained in exchange of operating lease obligations ​ ​ 9,753 ​ ​ — ​ The accompanying notes are an integral part of the condensed consolidated financial statements. ​ 8 Table of Contents Editas Medicine, Inc. Notes to Condensed Consolidated Financial Statements (unaudited) ​ 1. Nature of Business ​ Editas Medicine, Inc. (the “Company”) is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, a wholly-owned subsidiary of the Bristol Myers Squibb Company (“Juno Therapeutics”), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (together with its affiliates, “Allergan”), which was terminated in August 2020. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products. Liquidity ​ In May 2021, the Company entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $ 300.0 million (the “ATM Facility”). As of September 30, 2021, the Company has no t sold any shares of its common stock under the ATM Facility. ​ In January 2021, the Company completed a public offering whereby it sold 3,500,000 shares of its common stock and received net proceeds of approximately $ 216.9 million. In February 2021, the underwriters in the public offering exercised their option to purchase an additional 525,000 shares, resulting in additional net proceeds to the Company of approximately $ 32.6 million. ​ The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities at September 30, 2021 and anticipated interest income will enable it to fund its operating expenses and capital expenditure requirements well into 2023 . The Company had an accumulated deficit of $ 816.3 million at September 30, 2021, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. ​ 9 Table of Contents 2. Summary of Significant Accounting Policies ​ Unaudited Interim Financial Information ​ The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”). ​ The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Editas Securities Corporation. All intercompany transactions and balances of the subsidiary have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended September 30, 2021 and 2020 are referred to as the third quarter of 2021 and 2020, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. ​ Summary of Significant Accounting Policies ​ The Company’s significant accounting policies are described in Note 2, “Summary of significant accounting policies,” to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report. ​ ​ ​ 3. Cash Equivalents and Marketable Securities ​ Cash equivalents and marketable securities consisted of the following at September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance ​ ​ Gross ​ Gross ​ ​ ​ ​ Amortized ​ for Credit ​ ​ Unrealized ​ Unrealized ​ Fair September 30, 2021 ​ Cost ​ Losses ​ ​ Gains ​ Losses ​ Value Cash equivalents and marketable securities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 259,884 ​ $ — ​ ​ $ — ​ $ — ​ $ 259,884 U.S. Treasuries ​ ​ 109,060 ​ ​ — ​ ​ ​ 4 ​ ​ ( 15 ) ​ ​ 109,049 Government agency securities ​ ​ 118,708 ​ ​ — ​ ​ ​ 1 ​ ​ ( 17 ) ​ ​ 118,692 Commercial Paper ​ ​ 101,167 ​ ​ — ​ ​ ​ 3 ​ ​ ( 6 ) ​ ​ 101,164 Corporate notes/bonds ​ ​ 68,284 ​ ​ — ​ ​ ​ 2 ​ ​ ( 36 ) ​ ​ 68,250 Total ​ $ 657,103 ​ $ — ​ ​ $ 10 ​ $ ( 74 ) ​ $ 657,039 ​ 10 Table of Contents Cash equivalents and marketable securities consisted of the following at December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance ​ ​ Gross ​ Gross ​ ​ ​ ​ Amortized ​ for Credit ​ ​ Unrealized ​ Unrealized ​ Fair December 31, 2020 ​ Cost ​ Losses ​ ​ Gains ​ Losses ​ Value Cash equivalents and marketable securities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 139,682 ​ $ — ​ ​ $ — ​ $ — ​ $ 139,682 U.S. Treasuries ​ ​ 180,376 ​ ​ — ​ ​ ​ 8 ​ ​ ( 11 ) ​ ​ 180,373 Government agency securities ​ ​ 107,665 ​ ​ — ​ ​ ​ — ​ ​ ( 20 ) ​ ​ 107,645 Commercial paper ​ ​ 41,912 ​ ​ — ​ ​ ​ — ​ ​ ( 8 ) ​ ​ 41,904 Corporate notes/bonds ​ ​ 42,185 ​ ​ — ​ ​ ​ 10 ​ ​ ( 25 ) ​ ​ 42,170 Total ​ $ 511,820 ​ $ — ​ ​ $ 18 ​ $ ( 64 ) ​ $ 511,774 ​ As of September 30, 2021, the Company did no t hold any marketable securities that had been in an unrealized loss position for more than twelve months. Furthermore, the Company has determined that there were no material changes in the credit risk of the debt securities. As of September 30, 2021, the Company holds 29 securities with an aggregate fair value of $ 99.2 million that had remaining maturities between one and two years . ​ There were no realized gains or losses on available-for-sale securities during the nine months ended September 30, 2021 or 2020. ​ 4. Fair Value Measurements ​ Assets measured at fair value on a recurring basis as of September 30, 2021 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices Significant ​ ​ ​ ​ ​ ​ ​ in Active ​ Other ​ Significant ​ ​ ​ ​ ​ Markets for ​ Observable ​ Unobservable ​ ​ September 30, ​ Identical Assets ​ Inputs ​ Inputs Financial Assets ​ 2021 ​ (Level 1) ​ (Level 2) ​ (Level 3) Cash equivalents: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 259,884 ​ $ 259,884 ​ $ — ​ $ — Marketable securities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Treasuries ​ ​ 109,049 ​ ​ 109,049 ​ ​ — ​ ​ — Government agency securities ​ ​ 118,692 ​ ​ — ​ ​ 118,692 ​ ​ — Commercial paper ​ ​ 101,164 ​ ​ — ​ ​ 101,164 ​ ​ — Corporate notes/bonds ​ ​ 68,250 ​ ​ — ​ ​ 68,250 ​ ​ — Restricted cash and other non-current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ ​ 3,877 ​ ​ 3,877 ​ ​ — ​ ​ — Total financial assets ​ $ 660,916 ​ $ 372,810 ​ $ 288,106 ​ $ — ​ 11 Table of Contents Assets measured at fair value on a recurring basis as of December 31, 2020 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices Significant ​ ​ ​ ​ ​ ​ ​ in Active ​ Other ​ Significant ​ ​ ​ ​ ​ Markets for ​ Observable ​ Unobservable ​ ​ December 31, ​ Identical Assets ​ Inputs ​ Inputs Financial Assets ​ 2020 ​ (Level 1) ​ (Level 2) ​ (Level 3) Cash equivalents: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 139,682 ​ $ 139,682 ​ $ — ​ $ — Marketable securities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Treasuries ​ ​ 180,373 ​ ​ 180,373 ​ ​ — ​ ​ — Government agency securities ​ ​ 107,645 ​ ​ — ​ ​ 107,645 ​ ​ — Commercial paper ​ ​ 41,904 ​ ​ — ​ ​ 41,904 ​ ​ — Corporate bonds ​ ​ 42,170 ​ ​ — ​ ​ 42,170 ​ ​ — Restricted cash and other non-current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ ​ 3,877 ​ ​ 3,877 ​ ​ — ​ ​ — Total financial assets ​ $ 515,651 ​ $ 323,932 ​ $ 191,719 ​ $ — ​ ​ ​ ​ 5. Accrued Expenses ​ Accrued expenses consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ September 30, ​ December 31, ​ 2021 2020 Employee related expenses ​ $ 9,639 ​ $ 5,323 External research and development expenses ​ ​ 2,381 ​ 12,820 Intellectual property and patent related fees ​ ​ 1,606 ​ ​ 4,240 Professional service expenses ​ ​ 640 ​ ​ 533 Other expenses ​ ​ 271 ​ ​ 359 Sublicensing expenses ​ ​ 38 ​ ​ 771 Total accrued expenses ​ $ 14,575 ​ $ 24,046 ​ ​ ​ ​ ​ ​ ​ ​ 12 Table of Contents 6. Property and Equipment, net ​ Property and equipment, net consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ September 30, ​ December 31, ​ 2021 2020 Laboratory equipment ​ $ 20,647 ​ $ 18,433 Leasehold improvements ​ ​ 5,427 ​ ​ 4,967 Construction-in-progress ​ 2,360 ​ 500 Computer equipment ​ ​ 858 ​ ​ 858 Furniture and office equipment ​ ​ 264 ​ ​ 239 Software ​ 118 ​ 118 Total property and equipment ​ 29,674 ​ 25,115 Less: accumulated depreciation ​ ( 14,043 ) ​ ( 11,095 ) Property and equipment, net ​ $ 15,631 ​ $ 14,020 ​ ​ 7. Commitments and Contingencies ​ The Company is a party to a number of license agreements under which the Company licenses patents, patent applications and other intellectual property from third parties. As such, the Company is obligated to pay licensors for various costs including upfront licenses fees, annual license fees, certain licensor expense reimbursements, success payments, research funding payments, and milestones triggerable upon certain development, regulatory, and commercial events as well as royalties on future products. These contracts are generally cancellable, with notice, at the Company’s option and do not have significant cancellation penalties. The terms and conditions as well as the accounting analysis for the Company’s significant commitments and contingencies are described in Note 8, “Commitments and Contingencies” to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report. ​ Licensor Expense Reimbursement ​ The Company is obligated to reimburse The Broad Institute, Inc. (“Broad”) and the President and Fellows of Harvard College (“Harvard”) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the license agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. The Company incurred an aggregate of $ 1.8 million and $ 9.0 million in expense during the three and nine months ended September 30, 2021, respectively, for such reimbursement. The Company incurred an aggregate of $ 2.6 million and $ 9.3 million in expense during the three and nine months ended September 30, 2020, respectively, for such reimbursement. ​ 8 . Collaboration and Profit-Sharing Agreements ​ The Company has entered into multiple collaborations, out-licenses and strategic alliances with third parties that typically involve payments to or from the Company, including up-front payments, payments for research and development services, option payments, milestone payments and royalty payments to or from the Company. The terms and conditions as well as the accounting analysis for the Company’s significant collaborations, out-licenses and strategic alliances are described in Note 9, “Collaboration and Profit-Sharing Agreements” to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report. ​ ​ ​ 13 Table of Contents Collaboration Revenue ​ As of September 30, 2021, the Company’s contract liabilities were primarily related to the Company’s collaboration with Juno Therapeutics. The following table presents changes in the Company’s accounts receivable and contract liabilities for the nine months ended September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the nine months ended September 30, 2021 Balance at December 31, 2020 ​ Additions ​ Deductions ​ Balance at September 30, 2021 Accounts receivable $ 6,048 ​ $ 390 ​ $ ( 6,187 ) ​ $ 251 Contract liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred revenue $ 94,927 ​ $ — ​ $ ( 11,372 ) ​ $ 83,555 ​ During the three and nine months ended September 30, 2021, the Company recognized the following collaboration revenue (in thousands): ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended Revenue recognized in the period from: September 30, 2021 Amounts included in deferred revenue at the beginning of the period $ 5,666 ​ $ 11,372 Performance obligations satisfied in previous periods $ — ​ $ — ​ ​ 9 . Stock-based Compensation ​ Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ ​ 2021 ​ 2020 ​ 2021 ​ 2020 Research and development ​ $ 4,552 ​ $ 2,938 ​ $ 12,689 ​ $ 8,668 General and administrative ​ 5,460 ​ 2,908 ​ 23,053 ​ 8,815 Total stock-based compensation expense ​ $ 10,012 ​ $ 5,846 ​ $ 35,742 ​ $ 17,483 ​ Restricted Stock and Restricted Stock Unit Awards ​ The following is a summary of restricted stock and restricted stock unit awards activity for the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant Date ​ ​ ​ ​ Fair Value ​ ​ Shares ​ Per Share Unvested restricted stock and restricted stock unit awards as of December 31, 2020 507,450 ​ $ 27.35 Issued 614,775 ​ $ 48.12 Vested ( 191,075 ) ​ $ 31.08 Forfeited ​ ( 180,694 ) ​ $ 38.70 Unvested restricted stock and restricted stock unit awards as of September 30, 2021 750,456 ​ $ 41.33 ​ The restricted stock and restricted stock units granted in the nine months ended September 30, 2021 include 226,747 units granted to certain employees that contain performance-based vesting provisions. The Company recognizes the fair value of the performance-based units through the expected achievement date if the performance-based vesting provisions are deemed probable. ​ As of September 30, 2021, total unrecognized compensation expense related to unvested restricted stock and restricted stock unit awards was $ 18.7 million, which the Company expects to recognize over a remaining weighted-average period of 2.1 years. 14 Table of Contents ​ Stock Options ​ The following is a summary of stock option activity for the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Remaining Aggregate Intrinsic ​ ​ Shares ​ Exercise Price ​ Contractual Life (years) ​ Value (in thousands) Outstanding at December 31, 2020 3,912,257 ​ $ 27.26 ​ 7.9 ​ $ 167,640 Granted ​ 1,206,841 ​ $ 45.58 ​ ​ ​ ​ ​ Exercised ​ ( 1,218,120 ) ​ $ 25.50 ​ ​ ​ ​ ​ Cancelled ​ ( 817,563 ) ​ $ 30.83 ​ ​ ​ ​ ​ Outstanding at September 30, 2021 3,083,415 ​ $ 34.18 ​ 7.8 ​ $ 28,399 Exercisable at September 30, 2021 1,318,174 ​ $ 28.58 ​ 7.0 ​ $ 17,411 ​ The stock options granted in the nine months ended September 30, 2021 include option grants to the Company’s Chief Executive Officer to purchase 196,637 and 341,978 shares of the Company’s common stock that contained market-based vesting provisions and performance-based vesting provisions, respectively. The Company recognizes the fair value of the market-based options over the earlier of the derived service period, valued using the Monte-Carlo simulation model, or when the market-based vesting conditions are met. The Company recognizes the fair value of the performance-based options through the expected achievement date if the performance-based vesting provisions are deemed probable. ​ As of September 30, 2021, total unrecognized compensation expense related to stock options was $ 33.3 million, which the Company expects to recognize over a remaining weighted-average period of 2.5 years. ​ 10. Net (Loss) Income per Share ​ Basic net (loss) income per common share is calculated by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net (loss) income per share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic (loss) income per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted (loss) income per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ ​ 2021 ​ 2020 ​ 2021 ​ 2020 Net (loss) income ​ $ ( 39,082 ) ​ $ 7,819 ​ $ ( 151,066 ) ​ $ ( 53,477 ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding, basic ​ 68,219,742 ​ ​ 62,144,118 ​ ​ 67,371,246 ​ ​ 57,377,581 Dilutive effect of outstanding stock options ​ ​ — ​ ​ 414,640 ​ ​ — ​ ​ — Dilutive effect of unvested restricted stock and restricted stock unit awards ​ — ​ 138,415 ​ — ​ — Weighted average common shares outstanding, diluted ​ ​ 68,219,742 ​ ​ 62,697,173 ​ ​ 67,371,246 ​ ​ 57,377,581 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net (loss) income per share, basic ​ $ ( 0.57 ) ​ $ 0.13 ​ $ ( 2.24 ) ​ $ ( 0.93 ) Net (loss) income per share, diluted ​ $ ( 0.57 ) ​ $ 0.12 ​ $ ( 2.24 ) ​ $ ( 0.93 ) 15 Table of Contents ​ ​ The following common stock equivalents were excluded from the calculation of diluted net (loss) income per share allocable to common stockholders because their inclusion would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Nine months Ended ​ ​ September 30, ​ September 30, ​ 2021 ​ 2020 ​ 2021 2020 Unvested restricted stock and restricted stock unit awards 750,456 ​ 371,463 ​ 750,456 509,878 Outstanding stock options 3,083,415 ​ 3,626,151 ​ 3,083,415 4,040,791 Total 3,833,871 ​ 3,997,614 ​ 3,833,871 4,550,669 ​ ​ 16 Table of Contents